News & Updates

The JAK inhibitor upadacitinib brought sustained remission in the first 52 weeks of the phase III SELECT-GCA study of patients with new-onset or relapsing giant cell arteritis (GCA).

The use of abatacept as a first-line biologic treatment appears to result in greater remission in rheumatoid arthritis (RA), especially if the drug is used continuously, as shown in a real-world study from Taiwan.

Hysterosalpingography (HSG) with an oil-based contrast medium yields a significantly higher rate of ongoing pregnancy and live birth than HSG with a water-soluble contrast medium, according to a study presented at ESHRE 2024.

In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.

In the treatment of genitourinary syndrome of menopause (GSM), the nonhormone alternative vaginal hyaluronic acid is equally efficacious as the treatment standard vaginal oestrogen, while being well-tolerated, as shown in a pilot study.

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.